AU2014225320A1 - Methods of treating acute kidney injury - Google Patents

Methods of treating acute kidney injury Download PDF

Info

Publication number
AU2014225320A1
AU2014225320A1 AU2014225320A AU2014225320A AU2014225320A1 AU 2014225320 A1 AU2014225320 A1 AU 2014225320A1 AU 2014225320 A AU2014225320 A AU 2014225320A AU 2014225320 A AU2014225320 A AU 2014225320A AU 2014225320 A1 AU2014225320 A1 AU 2014225320A1
Authority
AU
Australia
Prior art keywords
injury
subject
renal
ischemia
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014225320A
Other languages
English (en)
Inventor
Denni ANDRESS
Richard A. ZAGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Fred Hutchinson Cancer Center
Original Assignee
AbbVie Inc
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc, Fred Hutchinson Cancer Center filed Critical AbbVie Inc
Publication of AU2014225320A1 publication Critical patent/AU2014225320A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7038—Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2014225320A 2013-03-08 2014-03-10 Methods of treating acute kidney injury Abandoned AU2014225320A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775174P 2013-03-08 2013-03-08
US61/775,174 2013-03-08
PCT/US2014/022688 WO2014138738A1 (en) 2013-03-08 2014-03-10 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
AU2014225320A1 true AU2014225320A1 (en) 2015-08-06

Family

ID=51492045

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014225320A Abandoned AU2014225320A1 (en) 2013-03-08 2014-03-10 Methods of treating acute kidney injury

Country Status (10)

Country Link
US (1) US20160015701A1 (enExample)
EP (1) EP2964671A4 (enExample)
JP (1) JP2016512201A (enExample)
CN (1) CN105324395A (enExample)
AU (1) AU2014225320A1 (enExample)
BR (1) BR112015020788A2 (enExample)
CA (1) CA2901922A1 (enExample)
HK (1) HK1220209A1 (enExample)
MX (1) MX2015011730A (enExample)
WO (1) WO2014138738A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909871A1 (en) 2013-04-30 2014-11-06 Abbvie Inc. Methods for improving lipid profiles using atrasentan
MX2017005884A (es) * 2014-11-07 2017-06-26 Abbvie Inc Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.
EP3235496A1 (en) 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
WO2018067857A1 (en) * 2016-10-05 2018-04-12 Mitobridge, Inc. Methods of treating acute kidney injury
KR102177349B1 (ko) * 2018-02-13 2020-11-12 서울대학교병원 체세포 복제 효율 증진용 조성물
US10978176B2 (en) 2018-06-29 2021-04-13 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline
WO2021091791A1 (en) * 2019-11-06 2021-05-14 Northwestern University Inhibition of the ve-ptp phosphatase protects the kidney from ischemia-reperfusion injury
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
MX2022007471A (es) * 2019-12-17 2022-08-17 Chinook Therapeutics Inc Metodos de tratamiento de la nefropatia por iga con atrasentan.
US20230270718A1 (en) * 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
CN113209111A (zh) * 2021-05-14 2021-08-06 上海海糖生物医药科技有限公司 一种褐藻寡糖的应用
CN115005157B (zh) * 2022-06-02 2023-12-26 上海交通大学医学院附属新华医院 一种低氧致急性肾损伤动物模型的构建方法
CN116731117B (zh) * 2023-06-19 2024-05-10 武汉大学 Kim-1靶向性多肽及其在急性肾损伤中肾靶向性的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
CA2563996A1 (en) * 2004-04-23 2005-11-10 Renal Diagnostic, Inc. An automated non- invasive real-time acute renal failure detection system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases

Also Published As

Publication number Publication date
BR112015020788A2 (pt) 2017-10-10
EP2964671A1 (en) 2016-01-13
WO2014138738A1 (en) 2014-09-12
WO2014138738A8 (en) 2015-12-30
EP2964671A4 (en) 2016-08-31
CA2901922A1 (en) 2014-09-12
CN105324395A (zh) 2016-02-10
JP2016512201A (ja) 2016-04-25
HK1220209A1 (zh) 2017-04-28
US20160015701A1 (en) 2016-01-21
MX2015011730A (es) 2016-04-04

Similar Documents

Publication Publication Date Title
US20160015701A1 (en) Methods of Treating Acute Kidney Injury
Harambat et al. Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease
Zager et al. Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury
Darisipudi et al. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease
Calvin et al. Contrast-induced acute kidney injury and diabetic nephropathy
OGDEN Donor and recipient function 2 to 4 years after renal homotransplantation: a paired study of 28 cases
She et al. Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease
Heering et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis
JP6822412B2 (ja) 妊娠高血圧腎症のための診断アッセイ及び治療
KR20190113955A (ko) 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
WO2012159107A1 (en) Inhibition of renal fibrosis
Xu et al. Progranulin protects against endotoxin-induced acute kidney injury by downregulating renal cell death and inflammatory responses in mice
Nakashima et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate
JP2014522879A (ja) 腎疾患の治療のためのカルジオトロフィン−１の使用
JP2016507486A (ja) 腎臓病の治療に使用されるアーテミシニンおよびその誘導体
Kunzendorf et al. The Th1-Th2 paradigm in 1998: law of nature or rule with exceptions.
BRPI0708645A2 (pt) composições e métodos para o tratamento de artrite reumatóide
CN103429242A (zh) 用于预防和治疗心脏肥大的方法和组合物
KR20180121539A (ko) 급성 신부전의 치료에 사용하기 위한 암브리센탄
Almeida et al. Successful use of mycophenolate mofetil as adjunct to prednisolone for treatment of acute kidney injury secondary to human serum albumin administration in a dog
JP2007512381A (ja) 医薬的組み合わせ
JP7356113B2 (ja) 薬剤及び該薬剤を用いて腎臓病を治療又は予防する方法
Ma et al. Pentoxifylline protects against loss of function and renal interstitial fibrosis in chronic experimental partial ureteral obstruction
EP1720552A2 (en) Methods for treating inflammatory and autoimmune diseases
TWI821836B (zh) 一種用於緩解或預防慢性腎臟病進展的藥物組合物及其用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted